Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 13, 2026 04:09 ET | Source: Research and Markets

Quetiapine (CAS 111974-69-7) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Applications, Manufacturing Method, Patents, Suppliers, Prices, End-users

Dublin, Jan. 13, 2026 (GLOBE NEWSWIRE) -- The "Quetiapine (CAS 111974-69-7) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ...
February 06, 2025 07:50 ET | Source: Transparency Market Research

Acute Agitation and Aggression Treatment Market to Exceed USD 8.2 Billion by 2034, Driven by Advancements in Rapid-Acting Therapies - Latest Report by Transparency Market Research Inc.

Wilmington, Delaware, Transparency Market Research Inc. – , Feb. 06, 2025 (GLOBE NEWSWIRE) -- The global acute agitation and aggression treatment market was valued at approximately US$ 5.0 billion...
July 01, 2021 08:00 ET | Source: OWP Pharmaceuticals, Inc.

OWP Pharmaceuticals Announces Patent Issuance for the First-Ever Oral Liquid Suspension of Quetiapine for the Treatment of Schizophrenia and Bipolar Disorder

NAPERVILLE, Ill., July 01, 2021 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and...
October 07, 2020 08:00 ET | Source: OWP Pharmaceuticals

OWP Pharmaceuticals Announces IND Approval for the First-Ever Liquid Oral Suspension Formulation of Quetiapine Fumarate for the Treatment of Schizophrenia and Bipolar Disorder

NAPERVILLE, Ill., Oct. 07, 2020 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and...
January 08, 2020 08:00 ET | Source: OWP Pharmaceuticals

OWP Pharmaceuticals Announces Pre-IND Acknowledgement and Patent Application for the First-Ever Liquid Oral Suspension Formulation of Quetiapine Fumarate for the Treatment of Schizophrenia and Bipolar Disorder

NAPERVILLE, Ill., Jan. 08, 2020 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc., a privately-held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and...